Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles

Journal of Gene Medicine

Volumn 11, Issue 9, 2009, Pages 754-763

  Huang, Rongqin ^a   Han, Liang ^a   Li, Jianhua ^b   Ren, Feiliang ^b   Ke, Weilun ^a   Jiang, Chen ^a   Pei, Yuanying ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI INSTITUTE FOR FOOD AND DRUG CONTROL   (China)

Author keywords

6 Hydroxydopamine; Brain gene therapy; Lactoferrin modified nanoparticles; Multiple dosing administrations; Parkinson's disease

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LACTOFERRIN; MONOAMINE; NEUROTRANSMITTER; OXIDOPAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIORAL RESEARCH; CELL LOSS; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; GENE THERAPY; LOCOMOTION; MALE; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; GENE THERAPY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; IMMUNOHISTOCHEMISTRY; LACTOFERRIN; MALE; NANOPARTICLES; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 70349501374     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1361     Document Type: Article

References (34)

1. Boado RJ. Blood-brain barrier transport of non-viral gene and RNAi therapeutics. Pharm Res 2007; 24: 1772-1787.
2. Pardridge WM. Blood-brain barrier delivery of protein and nonviral gene therapeutics with molecular Trojan horses. J Control Release 2007; 122: 345-348.
3. Yust-Katz S, Sthneer S, Melamed E, Djaldetti R. Long-term Parkinson's disease - time for optimism. Biomed Pharmacother 2008; 62: 233-235.
4. Bharali DJ, Klejbor I, Stachowiak EK, et al. Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. Proc Natl Acad Sci USA 2005; 102: 11539-11544.
5. Gonzalez-Barrios JA, Lindahl M, Bannon MJ, et al. Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats. Mol Ther 2006; 14: 857-865.
6. Oh S, Pluhar GE, McNeil EA, et al. Efficacy of nonviral gene transfer in the canine brain. J Neurosurg 2007; 107: 136-144.
7. Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron 2002; 36: 555-558.
8. Schlachetzki F, Zhang Y, Boado R, Pardridge WM. Gene therapy of the brain: the trans-vascular approach. Neurology 2004; 62: 1275-1281.
9. Shi N, Pardridge WM. Noninvasive gene targeting to the brain. Proc Natl Acad Sci USA 2000; 97: 7567-7572.
10. Zhang Y, Zhu C, Pardridge WM. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol Ther 2002; 6: 67-72.
11. Zhang Y, Schlachetzki F, Pardridge WM. Global non-viral gene transfer to the primate brain following intravenous administration. Mol Ther 2003; 7: 11-18.
12. Hatakeyama H, Akita H, Maruyama K, Suhara T, Harashima H. Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. Int J Pharm 2004; 281: 25-33.
13. da Cruz MT, Cardoso AL, de Almeida LP, Simões S, de Lima MC. Tf-lipoplex-mediated NGF gene transfer to the CNS: neuronal protection and recovery in an excitotoxic model of brain injury. Gene Ther 2005; 12: 1242-1252.
14. Cardoso AL, Simões S, de Almeida LP, et al. Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS. J Control Release 2008; 132: 113-123.
15. Kratzer I, Wernig K, Anzenboeck PU, et al. Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. J Control Release 2007; 117: 301-311.
16. Xia CF, Boado RJ, Zhang Y, Chu C, Pardridge WM. Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter. J Gene Med 2008; 10: 306-315.
17. Huang R, Ke W, Liu Y, Jiang C, Pei Y. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials 2008; 29: 238-246.
18. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201.
19. Carlsson T, Björklund T, Kirik D. Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy. Curr Gene Ther 2007; 7: 109-120.
20. García-Moreno JM, Páramo L, Chacón J. Oral L-dopa solution therapy of menstrual-related fluctuations in Parkinson's disease. Parkinsonism Relat Disord 2003; 10: 53-54.
21. Overstall PW, Clarke CE. Uncertainties in the pharmacotherapy of Parkinson's disease and how to solve them. Gerontology 2002; 48: 30-33.
22. Lindholm P, Voutilainen MH, Laurén J, et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007; 448: 73-77.
23. Acsadi G, Anguelov RA, Yang H, et al. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. Hum Gene Ther 2002; 13: 1047-1059.
24. Boado RJ, Zhang Y, Zhang Y, Wang Y, Pardridge WM. GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotechnol Bioeng 2008; 100: 387-396.
25. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 2005; 57: 298-302.
26. Albeck DS, Hoffer BJ, Quissell D, Sanders LA, Zerbe G, Granholm AC. A non-invasive transport system for GDNF across the blood-brain barrier. Neuroreport 1997; 8: 2293-2298.
27. Pisal DS, Yellepeddi VK, Kumar A, et al. Permeability of surface-modified polyamidoamine (PAMAM) dendrimers across Caco-2 cell monolayers. Int J Pharm 2008; 350: 113-121.
28. Huang RQ, Pei YY, Jiang C. Enhanced gene transfer into brain capillary endothelial cells using Antp-modified DNA-loaded nanoparticles. J Biomed Sci 2007; 14: 595-605.
29. Zhang Y, Calon F, Zhu C, Boado RJ, Pardridge WM. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther 2003; 14: 1-12.
30. Huang RQ, Qu YH, Ke WL, Zhu JH, Pei YY, Jiang C. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J 2007; 21: 1117-1125.
31. Romano G. Current development of nonviral-mediated gene transfer. Drug News Perspect 2007; 20: 227-231.
32. Luten J, van Nostrum CF, De Smedt SC, Hennink WE. Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J Control Release 2008; 126: 97-110.
33. Jung HS, Park KH, Cho YM, et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 2006; 69: 76-85.
34. Erbacher P, Bettinger T, Belguise-Valladier P, et al. Transfection and physical properties of various saccharide, poly (ethylene glycol), and antibody-derivatized polyethylenimines (PEI). J Gene Med 1999; 1: 210-222.